Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
QTREX Quantum (Nasdaq: QTEX) reaffirmed its October 1 disclosure and expects additional commercial agreements in the fourth quarter of 2026. The referenced binding definitive agreement is currently being finalized and now includes an expanded commercial scope.
QTREX is also advancing multiple additional commercial and technology agreements and broader business developments. The company expects the fourth quarter of 2026 to be its most active commercial period to date, with disclosures anticipated during November.
QTREX Quantum (Nasdaq: QTEX) received confirmation on October 16, 2026, that it had regained compliance with Nasdaq’s minimum bid price requirement.
The closing bid price of its ordinary shares was $1.00 per share or greater for 10 consecutive business days, from October 2 through October 15, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq has closed the matter. The company’s ordinary shares continue to be listed and traded on The Nasdaq Capital Market under QTEX.
QTREX Quantum (Nasdaq: QTEX) announced the full exercise of warrants covering 6,785,715 ordinary shares registered for resale in July 2026.
No investor holds warrants or other rights to acquire company shares, apart from an immaterial number of warrants issued to investment banks in prior fundraises. QTREX has no ATM offering program, which would sell shares into the market, and no convertible debt. Its approximately 70 million ordinary shares outstanding represent nearly its entire fully diluted equity capitalization, excluding the remaining warrants and standard employee equity awards and restricted share units.
QTREX Quantum (QTEX) announced full exercise of warrants covering 6,785,715 ordinary shares registered for resale in July 2026.
No investor holds warrants or other rights to acquire company shares, apart from an immaterial number of warrants issued to investment banks during prior fundraises. QTREX has no at-the-market offering program and no convertible debt. Approximately 70 million ordinary shares are outstanding, representing nearly its entire fully diluted equity capitalization, with exceptions for the remaining warrants and standard employee equity awards and restricted share units.
QTREX Quantum (QTEX) announced independent testing of its cryogenic interconnect at 20 millikelvin, a temperature used by superconducting quantum processors. The unnamed quantum computing company used its own cryogenic system, instruments and calibration standards. Channel isolation exceeded 100 dB across the 4–8 GHz band, with no crosstalk detected above the instrument noise floor. Performance remained unchanged through a second cooldown, bending and vacuum exposure.
QTREX and the testing company are finalizing a binding definitive agreement. QTREX expects to disclose the counterparty’s identity, business and full agreement within weeks, and to announce additional agreements with several quantum computing companies in the fourth quarter of 2026.
QTREX Quantum (QTEX) reported $1.55 million in revenue for the first half of 2026 after acquiring an AME business.
Revenue rose approximately 438% from $289,000 a year earlier. All first-half 2026 sales came from the acquired AME and Quantum segment during its first 86 days under QTREX. Gross profit was $944,000, for a 61% margin, while the company recorded a $6.4 million net loss. Cash, cash equivalents and deposits were $10.7 million at June 30, compared with $3.2 million at year-end 2025. Operating cash use fell to $3.9 million from $5.1 million a year earlier.
QTREX acquired the AME platform on April 6 for $2.0 million in cash at closing. It launched INSU300 and a dedicated AME system on September 23; two government and defense organizations are testing the material in their systems. An August 20 share offering raised approximately $9.2 million net, outside the June cash balance. QTREX expects to announce more commercial agreements and provide a 2027 outlook in the fourth quarter.
QTREX Quantum (QTEX) reported that one of Israel's three largest defense companies, described as a leading global aerospace and defense organization, has begun deploying QTREX's Additively Manufactured Electronics (AME) technology under a joint development program.
The first QTREX AME system is being installed at the partner’s facilities. The agreement includes exclusivity provisions and outlines a potential phased commercial pathway for broader AME system rollouts, with aggregate revenue for QTREX described as being in the tens of millions of dollars. The partner’s identity is not disclosed due to confidentiality obligations.
The joint program will adapt QTREX’s proprietary AME platform to the partner’s engineering, performance and reliability requirements through customized R&D, advanced materials and process optimization. Initial revenue is expected from immediate system deployment and recurring consumables, while later phases, subject to definitive agreements, contemplate procurement of tailored AME systems.
QTREX Quantum (Nasdaq: QTEX) entered into a definitive securities purchase agreement with an existing and a new global institutional investor to sell 11,111,111 ordinary shares in a registered direct offering. Gross proceeds are expected to be about $10 million before fees and expenses, with closing anticipated on or about August 21, 2026, subject to customary conditions.
According to QTREX Quantum, net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent, and the shares are being issued under an effective Form F-3 shelf registration statement via a prospectus supplement and base prospectus filed with the SEC.
QTREX Quantum (Nasdaq: QTEX) announced a patent-pending technology that directly converts its 3D-printed dielectric insulation into electrically conductive, graphene-like carbon using localized laser processing. Selected regions of insulation become patterned conductors without added materials or separate assembly steps, enabling monolithic stray-photon absorbers inside quantum packages.
Research at Northeastern University, using QTREX's AME platform and DF INSU300 material, produced conductive carbon under all 20 laser-processing conditions tested, with Raman spectroscopy confirming a graphene-like structure. QTREX targets commercial launch of DF INSU300 by the end of the third quarter of 2026 and is validating performance at cryogenic temperatures and high frequencies for integration into quantum-computing infrastructure.
QTREX Quantum (Nasdaq: QTEX) reported it is in discussions with a U.S. Department of Defense research laboratory to establish a joint quantum development program, targeting formalization in Q4 2026. The laboratory already operates QTREX’s additively manufactured electronics (AME) system, focused on high-density cryogenic interconnects and RF/microwave pathways for quantum systems.
The lab is distinct from the U.S. government facility disclosed on July 6, 2026, extending QTREX’s footprint to a second federal research institution. According to QTREX Quantum, the initiative aligns with its U.S. government presence, creation of QTREX USA, and broader strategy in quantum, defense, aerospace, and mission-critical markets.